HC Wainwright restated their neutral rating on shares of Eyenovia (NASDAQ:EYEN – Free Report) in a report published on Friday morning,Benzinga reports. HC Wainwright currently has a $2.00 target price ...
Combining Eyenovia's Optejet dispensing system with Betaliq's EyeSol medication delivery mechanism, the purchase would create ...
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology ...
Shares of Eyenovia (NASDAQ:EYEN) traded lower on Thursday after the ophthalmic product developer announced a non-binding agreement to seek a reverse merger with Betaliq, Inc., a privately held ...
Eyenovia on Thursday said it has signed a non-binding letter of intent to combine with clinical-stage pharmaceutical company Betaliq in an all-stock reverse merger. Eyenovia said Betaliq investors ...
Eyenovia, Inc. has announced a non-binding letter of intent for a potential reverse merger with Betaliq, Inc., which focuses on glaucoma treatments. If the merger is successful, it would create a ...
Eyenovia, Inc. NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of ...
Eyenovia (EYEN), has entered into a non-binding letter of intent contemplating a potential reverse merger transaction with Betaliq, a clinical ...
Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback